This was the stock's third consecutive day of losses.
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Irish Independent on MSN6h
Gilead gives its blessing to Poolbeg Pharma’s Hookpia merger dealUS biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...
The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...
TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...
Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.
CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...
Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $91.41 which represents a decrease of $-0.47 or -0.51% from the prior close of $91.88. The stock opened at $92.19 and touched a low of ...
We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...
Zacks.com on MSN3d
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for InvestorsIn the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.
GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback